Skip to main content
Premium Trial:

Request an Annual Quote

Tufts Health Plan Provides Positive Coverage Decision to BioTheranostics

NEW YORK (GenomeWeb News) – BioTheranostics today said that it has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerTypeID molecular cancer classifier.

Tufts has more than 1 million members.

CancerTypeID predicts tumor types in patients with metastatic cancers. The real time, RT-PCR based assay determines the tumor site of origin by using the differential expression of 92 genes, and among the tumor types the product classifies are melanoma, kidney, thyroid, ovary, brain, sarcoma, and others, according to BioTheranostics' website.

"With metastatic cancer, achieving diagnostic certainty is critical to optimize site-directed therapies that reduce costs and avoid ineffective therapies for both patients and payors," BioTheranostics' President and CEO Richard Ding said in a statement. "This announcement is part of our efforts to work with payors across the country to make this important diagnostic test available to clinicians and cancer patients, helping to support personalized medicine with the goal of improving outcomes."

The San Diego-headquartered firm announced earlier this month that it became an in-network provider of Highmark Health Services, and based on a Highmark member's individual benefits, the patient may have access to CancerTypeID as an in-network service.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.